Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial
Thursday, February 09, 2023
Creative Medical Technology Holdings announced that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy.
The Company believes that CELZ-201 leverages a unique approach to harness the power of Perinatal Tissue Derived Cells® (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion. The primary objective of the study is to evaluate CELZ-201 as a treatment for patients with newly diagnosed Type 1 Diabetes.
This trial with the perinatal cell product CELZ-201 if successful, is expected to provide promising treatments for many patients with type 1 diabetes.
The company sponsored trial will be conducted at the University of Miami Health System in conjunction with the Diabetes Research Institute.
